{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:34:17Z","timestamp":1784230457156,"version":"3.55.0"},"reference-count":33,"publisher":"Impact Journals, LLC","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,8,8]]},"DOI":"10.18632\/oncotarget.19036","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T23:19:34Z","timestamp":1499383174000},"page":"52026-52044","source":"Crossref","is-referenced-by-count":28,"title":["Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase"],"prefix":"10.18632","volume":"8","author":[{"given":"Ellen L.","family":"Weisberg","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Puissant","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sattler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Buhrlage","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Manley","sequence":"additional","affiliation":[{"name":"Novartis Institutes of Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Buonopane","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Daley","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Lazo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Christie","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Stegmaier","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Griffin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjh.12135","article-title":"Genetic profiling in acute myeloid leukaemia\u2014Where are we and what is its role in patient management","volume":"160","author":"Rowe","year":"2013","journal-title":"Br J Haematol"},{"key":"3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.blre.2012.11.001","article-title":"Mutational landscape of AML with normal cytogenetics: Biological and clinical implications","volume":"27","author":"Falini","year":"2013","journal-title":"Blood Rev"},{"key":"4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/JBM.S100283","article-title":"Midostaurin: an emerging treatment for acute myeloid leukemia patients","volume":"7","author":"Lazarus","year":"2016","journal-title":"J Blood Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2009.04.001","article-title":"FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML","volume":"12","author":"Griffin","year":"2009","journal-title":"Drug Resist Updat"},{"key":"6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Griffin","year":"2002","journal-title":"Cancer Cell"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Stone, Mandrekar, Sanford, Geyer, Bloomfield, Dohner, Thiede, Marcucci, Lo-Coco, Klisovic, Wei, Sierra, Sanz, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)\/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603\/RATIFY [Alliance]) (abstract). Paper presented at: American Society of Hematology (ASH) 57th Annual Meeting. December 3\u20136 2015. Orlando, FL, USA.","DOI":"10.1182\/blood.V126.23.6.6"},{"key":"8","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N\u2019-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Bhagwat","year":"2009","journal-title":"J Med Chem"},{"key":"9","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Shah","year":"2014","journal-title":"Proc Natl Acad Sci. USA"},{"key":"10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccr.2014.01.022","article-title":"SYK is a critical regulator of FLT3 in acute myeloid leukemia","volume":"25","author":"Galinsky","year":"2014","journal-title":"Cancer Cell"},{"key":"11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/378298a0","article-title":"Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk","volume":"378","author":"Tybulewicz","year":"1995","journal-title":"Nature"},{"key":"12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/378303a0","article-title":"Syk tyrosine kinase required for mouse viability and B-cell development","volume":"378","author":"Pawson","year":"1995","journal-title":"Nature"},{"key":"13","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1073\/pnas.92.11.5106","article-title":"Analysis of the interaction of ZAP-70 and syk protein-tyrosine kinases with the T-cell antigen receptor by plasmon resonance","volume":"92","author":"Chan","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1073\/pnas.97.4.1713","article-title":"Role of Syk in B-cell development and antigen-receptor signaling","volume":"97","author":"Goodnow","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2005.05883.x","article-title":"Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma","volume":"132","author":"Capella","year":"2006","journal-title":"Br J Haematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","article-title":"SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma","volume":"111","author":"Shipp","year":"2008","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","article-title":"Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia","volume":"69","author":"Dierks","year":"2009","journal-title":"Cancer Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ccr.2009.08.018","article-title":"Proteomic and genetic approaches identify Syk as an AML target","volume":"16","author":"DeAngelo","year":"2009","journal-title":"Cancer Cell"},{"key":"19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20092042","article-title":"The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma","volume":"207","author":"Ruland","year":"2010","journal-title":"J Exp Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2404045","article-title":"Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma","volume":"20","author":"Chott","year":"2006","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1046\/j.1365-2141.1999.01607.x","article-title":"An atypical myelodysplastic syndrome with t(9;12)(q22;p12) and TEL gene rearrangement","volume":"106","author":"Saito","year":"1999","journal-title":"Br J Haematol"},{"key":"22","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V97.4.1050","article-title":"Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12)","volume":"97","author":"Saito","year":"2001","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1084\/jem.20060967","article-title":"Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells","volume":"203","author":"Jumaa","year":"2006","journal-title":"J Exp Med"},{"key":"24","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1038\/bcj.2014.53","article-title":"Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice","volume":"4","author":"Duyster","year":"2014","journal-title":"Blood Cancer J"},{"key":"25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Radia","year":"2016","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Sun","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.111.188441","article-title":"Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis","volume":"340","author":"Sinha","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"28","doi-asserted-by":"crossref","first-page":"e25351","DOI":"10.1371\/journal.pone.0025351","article-title":"Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells","volume":"6","author":"Griffin","year":"2011","journal-title":"PLoS One"},{"key":"29","doi-asserted-by":"crossref","first-page":"32662","DOI":"10.1074\/jbc.274.46.32662","article-title":"SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling","volume":"274","author":"Scharenberg","year":"1999","journal-title":"J Biol Chem"},{"key":"30","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1093\/emboj\/cdf658","article-title":"BLNK: molecular scaffolding through \u201acis\u2019-mediated organization of signaling proteins","volume":"21","author":"Chan","year":"2002","journal-title":"EMBO J"},{"key":"31","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.leu.2400768","article-title":"Two acute monocytic leukemia (AML-M5a) cell lines (MOLM13 and MOLM14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23)","volume":"11","author":"Orita","year":"1997","journal-title":"Leukemia"},{"key":"32","first-page":"173","article-title":"Validation of a therapeutic target identified by gene expression based classification","volume":"3","author":"Korsmeyer","year":"2003","journal-title":"Cancer Cell"},{"key":"33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T21:32:32Z","timestamp":1589146352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":33,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2017,8,8]]}},"alternative-id":["19036","28881711"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19036","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]}}}